Award
NIH Reporter #3U01AG076789-03S1
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
Recipient
Not specified
Award Amount
$314,717.00
Ceiling
$314,717.00
Awarded
May 26, 2026
Identifier
3U01AG076789-03S1
A randomized controlled trial to evaluate NAD augmentation using NMN in older adults with diabetic kidney disease, focusing on safety and efficacy assessment.
Description
This project involves a phase 2a, randomized, placebo-controlled, double-blind trial to evaluate NAD augmentation using nicotinamide mononucleotide (NMN) in older adults with diabetic kidney disease. The study is fully enrolled, with follow-up ongoing for safety and efficacy assessment. The total award amount is approximately $314,717, with a focus on safety monitoring and study close-out activities.